medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-4-78-86medsovet-3120Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYПатология костно-мышечной системы: фокус на саркопению и остеосаркопениюMusculoskeletal system pathology: focus on sarcopenia and osteosarcopeniaТоропцоваН. В.ToroptsovaN. V.

Торопцова Наталья Владимировна - доктор медицинских наук, врач-ревматолог высшей квалификационной категории, заведующий лабораторией остеопороза отдела метаболических заболеваний костей и суставов.

115522, Москва, Каширское шоссе, д. 34а; тел.: +7 (495) 109-29-10

Toroptsova Natalia Vladimirovna - Dr. of Sci. (Med), rheumatologist of the highest qualification category, head of the osteoporosis laboratory of the Department of Metabolic Diseases of Bones and Joints.

115522, Moscow, Kashirskoe shosse, 34а; tel: +7 (495) 109-29-10

ФеклистовА. Ю.FeklistovA. Yu.

Феклистов Алексей Юрьевич - младший научный сотрудник, врач-ревматолог лаборатории остеопороза отдела метаболических заболеваний костей и суставов.

115522, Москва, Каширское шоссе, д. 34а; тел.: +7 (495) 109-29-10

Feklistov Alexey Yurievich - junior researcher, rheumatologist of the osteoporosis laboratory of the Department of Metabolic Diseases of Bones and Joints.

115522, Moscow, Kashirskoe shosse, 34а; tel: +7 (495) 109-29-10

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. НасоновойРоссияFederal State Budgetary Institution Research Institute of Rheumatology named after V.A. NasonovaRussian Federation201920082019047886Copyright © Торопцова Н.В., Феклистов А.Ю., 20192019Торопцова Н.В., Феклистов А.Ю.Toroptsova N.V., Feklistov A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/3120

В течение последних 40 лет уделяется большое внимание состоянию мышечной ткани и ее функции у пожилых людей, что связано с повышенным риском падений и переломов в данной популяции лиц. В 1989 г. был предложен термин «саркопения» для обозначения снижения массы и силы скелетных мышц в процессе старения, а в 2010 г. Европейская рабочая группа по изучению саркопении представила определение и диагностические критерии данного состояния. В 2016 г. саркопении был присвоен код М62.84 для ее обозначения как заболевания мышц в МКБ-10. Статья знакомит читателей с классификацией, факторами риска и методами диагностики данного заболевания, представлены обновленные критерии его диагностики, а также дано определение понятия «остеосаркопения». Описаны возможные методы профилактики и лечения для улучшения качества жизни больных, страдающих саркопенией и остеосаркопенией.

Over the past 40 years, much attention has been paid to the condition of muscle tissue and its function in older people, which is associated with an increased risk of falls and fractures in this population of people. The term «sarcopenia» was proposed in 1989 to denote a decrease in the weight and strength of skeletal muscles in the process of aging, and in 2010 European Working Group on Sarcopenia provided a definition and diagnostic criteria for this condition. In 2016, sarcopenia was assigned a code M62.84 to designate it as a muscle disease in the ICD-10. The article introduces readers to the classification, risk factors and methods of diagnosis of the disease, provides updated criteria for its diagnosis, and defines the concept of «osteosarcopenia». Possible methods of prevention and treatment to improve the quality of life of patients suffering from sarcopenia and osteosarcopenia are described.

саркопенияостеосаркопенияфакторы рискакритерии диагностикипрепараты витамина Dsarcopeniaosteosarcopeniarisk factorsdiagnostic criteriavitamin D drugsReferencesRosenberg I. Summary comments. Am. J. Clin. Nutr. 1989;50:1231-1233.Rosenberg I. Summary comments. Am. J. Clin. Nutr. 1989;50:1231-1233.Schaap L.A., van Schoor N.M., Lips P. et al. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018;73:1199-204.Schaap L.A., van Schoor N.M., Lips P. et al. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018;73:1199-204.Malmstrom T.K., Miller D.K., Simonsick E.M. et al. SARC-F: asymptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28-36.Malmstrom T.K., Miller D.K., Simonsick E.M. et al. SARC-F: asymptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28-36.Bahat G., Ilhan B. Sarcopenia and the cardio-metabolic syndrome: a narrative review. Eur Geriatr Med. 2016;6:220-23.Bahat G., Ilhan B. Sarcopenia and the cardio-metabolic syndrome: a narrative review. Eur Geriatr Med. 2016;6:220-23.Bone A.E., Hepgul N., Kon S. et al. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017;14:85-99.Bone A.E., Hepgul N., Kon S. et al. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2017;14:85-99.Chang K.V., Hsu T.H., Wu W.T. et al. Association between sarcopenia and cognitive impairment: a systematic review and metaanalysis. J Am Med Dir Assoc. 2016;17:1164.e7-64.e15.Chang K.V., Hsu T.H., Wu W.T. et al. Association between sarcopenia and cognitive impairment: a systematic review and metaanalysis. J Am Med Dir Assoc. 2016;17:1164.e7-64.e15.Dos Santos L., Cyrino E.S., Antunes M. et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017;8:245-50.Dos Santos L., Cyrino E.S., Antunes M. et al. Sarcopenia and physical independence in older adults: the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017;8:245-50.Steffl M., Bohannon R.W., Sontakova L. et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:835-45.Steffl M., Bohannon R.W., Sontakova L. et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:835-45.De Buyser S.L., Petrovic M., Taes YE. et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016;45:602-8.De Buyser S.L., Petrovic M., Taes YE. et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016;45:602-8.Antunes A.C., Araujo D.A., Verissimo M.T. et al. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet. 2017;74:46-50.Antunes A.C., Araujo D.A., Verissimo M.T. et al. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet. 2017;74:46-50.Steffl M., Sima J., Shiells K. et al. The increase in health care costs associated with muscle weakness in older people without long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe (SHARE). Clin IntervAging. 2017;12:2003-07.Steffl M., Sima J., Shiells K. et al. The increase in health care costs associated with muscle weakness in older people without long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe (SHARE). Clin IntervAging. 2017;12:2003-07.Cruz-Jentoft AJ., Baeyens J.P., Bauer J.M. et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412-423. doi: 10.1093/age-ing/afq034.Cruz-Jentoft AJ., Baeyens J.P., Bauer J.M. et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older people. Age Ageing. 2010;39(4):412-423. doi: 10.1093/age-ing/afq034.Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512-514. doi.org/10.1002/jcsm.12147.Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512-514. doi.org/10.1002/jcsm.12147.Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16;16:21. doi: 10.11 86/s40200-017-0302-x.eCollection 2017.Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16;16:21. doi: 10.11 86/s40200-017-0302-x.eCollection 2017.Landi F., Calvani R., Tosato M. et al. Impact of physical function impairment and multimorbidity on mortality among communityliving older persons with sarcopaenia: results from the ilSIRENTE prospective cohort study. BMJ Open. 2016;6:e008281. doi:10.1136/bmjopen-2015-008281.Landi F., Calvani R., Tosato M. et al. Impact of physical function impairment and multimorbidity on mortality among communityliving older persons with sarcopaenia: results from the ilSIRENTE prospective cohort study. BMJ Open. 2016;6:e008281. doi:10.1136/bmjopen-2015-008281.Cruz-Jentoft AJ., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.Cruz-Jentoft AJ., Bahat G., Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.Beaudart C., McCloskey E., Bruyere O. et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16:170. doi: 10.1186/s12877-016-0349-4.Beaudart C., McCloskey E., Bruyere O. et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16:170. doi: 10.1186/s12877-016-0349-4.Cesari M., Kritchevsky S.B., Newman A.B. et al. Added value of physical performance measures in predicting adverse healthrelated events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57:251-9. doi.org/10.1111/j.1532-5415.2008.02126.x.Cesari M., Kritchevsky S.B., Newman A.B. et al. Added value of physical performance measures in predicting adverse healthrelated events: results from the health, aging and body composition study. J Am Geriatr Soc. 2009;57:251-9. doi.org/10.1111/j.1532-5415.2008.02126.x.Jones CJ., Rikli R.E., Beam W.C. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113-9.Jones CJ., Rikli R.E., Beam W.C. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70:113-9.Pavasini R., Guralnik J., Brown J.C. et al. Short physical performance battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14:215. doi.org/10.1186/s12916-016-0763-7.Pavasini R., Guralnik J., Brown J.C. et al. Short physical performance battery and all-cause mortality: systematic review and meta-analysis. BMC Med. 2016;14:215. doi.org/10.1186/s12916-016-0763-7.Vestergaard S., Patel K.V., Bandinelli S. et al. Characteristics of 400-meter walk test performance and subsequent mortality in older adults. Rejuvenation Res. 2009;12:177-84.Vestergaard S., Patel K.V., Bandinelli S. et al. Characteristics of 400-meter walk test performance and subsequent mortality in older adults. Rejuvenation Res. 2009;12:177-84.Landi F., Onder G., Russo A. et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014;33:539-44.Landi F., Onder G., Russo A. et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014;33:539-44.Binkley N., Buehring B. Beyond FRAX: It’s time to consider ‘sarco-osteopenia’. J Clin Densitom. 2009;12(4):413-16.Binkley N., Buehring B. Beyond FRAX: It’s time to consider ‘sarco-osteopenia’. J Clin Densitom. 2009;12(4):413-16.Huo Y.R., Suriyaarachchi P., Gomez F. et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16(4):290-95.Huo Y.R., Suriyaarachchi P., Gomez F. et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16(4):290-95.Demontiero O., Boersma D., Suriyaarachchi P. et al. Clinical outcomes of impaired muscle and bone interactions. Clin Rev Bone Miner Metab. 2014;12:86-92. doi: 10.1007/s12018-014-9164-7.Demontiero O., Boersma D., Suriyaarachchi P. et al. Clinical outcomes of impaired muscle and bone interactions. Clin Rev Bone Miner Metab. 2014;12:86-92. doi: 10.1007/s12018-014-9164-7.Mera P, Laue K., Ferron M. et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23(6):1078-1092. doi: 10.1016/j.cmet.2016.05.004.Mera P, Laue K., Ferron M. et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. 2016;23(6):1078-1092. doi: 10.1016/j.cmet.2016.05.004.Tagliaferri C., Wittrant Y., Davicco MJ. et al. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015;21:55-57. doi: 10.1016/j.arr.2015.03.002.Tagliaferri C., Wittrant Y., Davicco MJ. et al. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015;21:55-57. doi: 10.1016/j.arr.2015.03.002.Hassan E.B., Duque G. Osteosarcopenia: A new geriatric syndrome. Aust Fam Physician. 2017 Nov;46(11):849-853.Hassan E.B., Duque G. Osteosarcopenia: A new geriatric syndrome. Aust Fam Physician. 2017 Nov;46(11):849-853.Beaudart C., Dawson A., Shaw C. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817-1833. doi 10.1007/s00198-017-3980-9.Beaudart C., Dawson A., Shaw C. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28:1817-1833. doi 10.1007/s00198-017-3980-9.Hickson M. Conference on ‘Nutrition and age-related muscle loss, sarcopenia and cachexia’ Symposium 3: Nutrition for prevention and interventions for sarcopenia and cachexia Nutritional interventions in sarcopenia: a critical review. Proceedings of the Nutrition Society. 2015;74:378-386. doi:10.1017/S0029665115002049.Hickson M. Conference on ‘Nutrition and age-related muscle loss, sarcopenia and cachexia’ Symposium 3: Nutrition for prevention and interventions for sarcopenia and cachexia Nutritional interventions in sarcopenia: a critical review. Proceedings of the Nutrition Society. 2015;74:378-386. doi:10.1017/S0029665115002049.Bauer J., Biolo G., Cederholm T., Cesari M., Cruz-Jentoft AJ., Morley J.E. et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14(8):542e59. http//dx.doi.org/10.1016/j.jamda.2013.05.021.Bauer J., Biolo G., Cederholm T., Cesari M., Cruz-Jentoft AJ., Morley J.E. et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14(8):542e59. http//dx.doi.org/10.1016/j.jamda.2013.05.021.Gerdhem P., Ringsberg K.A., Obrant KJ., Akesson K.Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OprA Study of Elderly Women. Osteoporos. Int. 2005;16(11):1425-1431.Gerdhem P., Ringsberg K.A., Obrant KJ., Akesson K.Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OprA Study of Elderly Women. Osteoporos. Int. 2005;16(11):1425-1431.Nakamura K., Oshiki R., Hatakeyama K. et al. Vitamin D status, postural sway, and the incidence of falls in elderly community-dwelling Japanese women. Arch. Osteoporos. 2006;1:21-27.Nakamura K., Oshiki R., Hatakeyama K. et al. Vitamin D status, postural sway, and the incidence of falls in elderly community-dwelling Japanese women. Arch. Osteoporos. 2006;1:21-27.Udowenko M., Trojian T. Vitamin D: extent of deficiency, effect on muscle function, bone health, performance, and injury prevention. Conn Med. 2010 Sep;74(8):477-80.Udowenko M., Trojian T. Vitamin D: extent of deficiency, effect on muscle function, bone health, performance, and injury prevention. Conn Med. 2010 Sep;74(8):477-80.Jackson C., Gaugris S., Sen S.S., Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM. 2007;100(4):185-192.Jackson C., Gaugris S., Sen S.S., Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM. 2007;100(4):185-192.Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., Wong J.B., Egli A., Kiel D.P., Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.Bunout D., Barrera G., Leiva L. et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol. 2006;41:746-752. doi:10.1016/j.exger.2006.05.001.Bunout D., Barrera G., Leiva L. et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol. 2006;41:746-752. doi:10.1016/j.exger.2006.05.001.Binder E.F. Implementing a structured exercice program for frail nursing home residents with dementia: issues and challenge. JAPA. 1996;3(4):383-395. doi:10.1123/japa.3.4.383.Binder E.F. Implementing a structured exercice program for frail nursing home residents with dementia: issues and challenge. JAPA. 1996;3(4):383-395. doi:10.1123/japa.3.4.383.Торопцова Н.В., Никитинская О.А. Остеопороз в реальной клинической практике: фокус на альфакальцидол. Фарматека. 2016;19(332):36-41. [Toroptsova N.V., Nikitinskaya O.A. Osteoporosis in real clinical practice: focus on alphacalcidol. Pharmacy [Farmateka]. 2016;19(332):36-41. (In Russ.)]Торопцова Н.В., Никитинская О.А. Остеопороз в реальной клинической практике: фокус на альфакальцидол. Фарматека. 2016;19(332):36-41. [Toroptsova N.V., Nikitinskaya O.A. Osteoporosis in real clinical practice: focus on alphacalcidol. Pharmacy [Farmateka]. 2016;19(332):36-41. (In Russ.)]Dukas L., Schacht E., Runge M. Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis. Osteoporos. Int. 2010;21(7):1237-1245.Dukas L., Schacht E., Runge M. Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis. Osteoporos. Int. 2010;21(7):1237-1245.Schacht E., Richy F., Reginster J.Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J. Musculoskelet. Neuronal. Interact. 2005;5(3):273-284.Schacht E., Richy F., Reginster J.Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J. Musculoskelet. Neuronal. Interact. 2005;5(3):273-284.Shibata T., Shira-Ishi A., Sato T., Masaki T., Sasaki A., Masuda Y., Hishiya A., Ishikura N., Higashi S., Uchida Y., Saito M., Ito M., Ogata E., Watanabe K., Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivoby decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res. 2002;17:622-629.Shibata T., Shira-Ishi A., Sato T., Masaki T., Sasaki A., Masuda Y., Hishiya A., Ishikura N., Higashi S., Uchida Y., Saito M., Ito M., Ogata E., Watanabe K., Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivoby decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res. 2002;17:622-629.Shiraishi A., Higashi S., Okawa H., Ogata E. The effect of 1-(OH)D3 on bone metabolism in par-athyroidectomized rats with continuous PTH infusion. Osteoporos. Int. 1997;7(Suppl.2):35.Shiraishi A., Higashi S., Okawa H., Ogata E. The effect of 1-(OH)D3 on bone metabolism in par-athyroidectomized rats with continuous PTH infusion. Osteoporos. Int. 1997;7(Suppl.2):35.Richy F., Ethgen O., Bruyere O., Reginster J.-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a metaanalysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15:301-310.Richy F., Ethgen O., Bruyere O., Reginster J.-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a metaanalysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15:301-310.Bischoff-Ferrari H.A., Borchers M., Gudat F., Dur-muller U., Stahelin H.B., Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19:265-269.Bischoff-Ferrari H.A., Borchers M., Gudat F., Dur-muller U., Stahelin H.B., Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res. 2004;19:265-269.Dukas L., Schacht E., Bischoff H.A. Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J. Nutrition Health and Aging. 2005;9:347-351.Dukas L., Schacht E., Bischoff H.A. Better functional mobility in community dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J. Nutrition Health and Aging. 2005;9:347-351.Sorensen O.H., Lund B., Saltin B. et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalcif-erol and calcium. Clin Sci 1979;56:157-161.Sorensen O.H., Lund B., Saltin B. et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalcif-erol and calcium. Clin Sci 1979;56:157-161.Verhaar HJJ., Samson M.M., Jansen PA.F., de Vreede PL., Manten J.W, Duursma S.A. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000;12:455-460.Verhaar HJJ., Samson M.M., Jansen PA.F., de Vreede PL., Manten J.W, Duursma S.A. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000;12:455-460.Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003;23:268-274.Scharla S.H., Schacht E., Bawey S., Kamilli I., Holle D., Lempert U.G. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003;23:268-274.Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., Thalmann B., Stahelin H.B. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52:230-236.Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., Thalmann B., Stahelin H.B. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52:230-236.Dukas L., Schacht E., Mazor Z., Stahelin H.B. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos. Int. 2005;16:198-203.Dukas L., Schacht E., Mazor Z., Stahelin H.B. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos. Int. 2005;16:198-203.Dukas L., Schacht E., Runge M., Ringe J.D. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60(8):519-25. doi: 10.1055/s-0031-1296321.Dukas L., Schacht E., Runge M., Ringe J.D. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60(8):519-25. doi: 10.1055/s-0031-1296321.Schacht E., Ringe J.D. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int. 2012 Jan;32(1):207-15. doi: 10.1007/s00296-010-1607-y.Schacht E., Ringe J.D. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int. 2012 Jan;32(1):207-15. doi: 10.1007/s00296-010-1607-y.Morley J.E. Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int. 2016;98(4): 319-33. doi: 10.1007/s00223-015-0022-5.Morley J.E. Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int. 2016;98(4): 319-33. doi: 10.1007/s00223-015-0022-5.

The authors declare that there are no conflicts of interest present.